DTIL – precision biosciences, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

DTIL

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/28

08:20 am

dtil

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Neutral Report

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Report

3/26

07:14 am

dtil

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]

High Report

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Report

3/26

07:01 am

dtil

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

High Report

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Report

3/25

11:28 am

dtil

Prendio-BioProcure Launches New Generative AI, Analytics, and Workflow Automation Capabilities Enhancing its Market Leading Life Sciences P2P Technology Solution [Yahoo! Finance]

Medium Report

Prendio-BioProcure Launches New Generative AI, Analytics, and Workflow Automation Capabilities Enhancing its Market Leading Life Sciences P2P Technology Solution [Yahoo! Finance]

Report

3/21

08:00 am

dtil

iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting

Low Report

iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting

Report

3/21

07:01 am

dtil

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Low Report

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Report

3/20

07:31 am

dtil

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 [Yahoo! Finance]

Medium Report

Report

3/20

07:01 am

dtil

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Medium Report

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Report

3/19

12:38 pm

dtil

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Low Report

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Report

3/19

07:01 am

dtil

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Medium Report

Report

3/17

07:01 am

dtil

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Low Report

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Report

3/12

08:00 am

dtil

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Low Report

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Report

2/24

07:01 am

dtil

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Medium Report

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Report

2/20

06:25 am

dtil

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate [Yahoo! Finance]

Medium Report

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate [Yahoo! Finance]

Report

2/19

11:42 am

dtil

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Low Report

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Report

2/19

07:17 am

dtil

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial [Yahoo! Finance]

Medium Report

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial [Yahoo! Finance]

Report

2/19

07:01 am

dtil

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Medium Report

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Report

1/29

07:01 am

dtil

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Low Report

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Report

1/10

08:03 am

dtil

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

High Report

Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.

Report

1/10

08:01 am

dtil

Precision BioSciences, Inc. (NASDAQ: DTIL) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $34.00 price target on the stock.

High Report

Precision BioSciences, Inc. (NASDAQ: DTIL) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $34.00 price target on the stock.

Report

1/9

10:01 am

dtil

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

High Report

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Report

1/9

08:00 am

dtil

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

High Report

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.